Relmada Therapeutics (RLMD) Tops Q3 EPS by 18c

Relmada Therapeutics (NASDAQ: RLMD) reported Q3 EPS of ($0.73), $0.18 better than the analyst estimate of ($0.91).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance